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Background: Anti-nuclear antibodies (ANA), anti-extractable nuclear antigens (ENA) and anti-
dsDNA antibodies are often associated with cutaneous lupus erythematosus (CLE), with variable 
frequency depending on skin subtype. However, specific data based on large case-series on the 
pathogenetic, diagnostic, and prognostic meaning of such autoantibodies are still lacking. 
Objective: To characterize the correlations between CLE subtypes as well as LE-non specific skin 
lesions and their autoantibody pattern. 
Methods: Epidemiological, clinical and immunopathological data of 619 Italian patients with CLE 
and LE-non specific skin lesions were analyzed. Differences in age, sex, clinical features and 
autoantibody profile were evaluated in each LE subgroup. 
Results: ANA (p<0.0001), anti-dsDNA (p<0.0001), ENA (p=0.001), anti-Sm (p=0.001), anti-RNP 
(p=0.004), anti-histone (p=0.005) antibodies were associated with SLE. A strong association 
between ANA (p<0.0001) and anti-dsDNA (p<0.0001) and female gender was also found: positive 
ANA and positive anti-dsDNA had a higher prevalence among females. 
Chronic CLE resulted to be negatively associated with ENA (OR=0.51, p<0.0001), anti-Ro/SSA 
(OR=0.49, p<0.0001) and anti-dsDNA (OR=0.37, p<0.0001). Intermittent CLE resulted to be 
negatively associated with ENA (OR=0.50, p=0.007) and ANA (OR=0.61, p=0.025). Subacute CLE 
resulted to be associated with ENA (OR=5.19, p<0.0001), anti-Ro/SSA (OR=3.83, p<0.0001), anti-
Smith (OR=2.95, p=0.004) and anti-RNP (OR=3.18, p=0.007). Acute CLE resulted to be strongly 
associated with anti-dsDNA (OR=6.0, p<0.0001) and ANA (OR=18.1, p<0.0001). 
LE-nonspecific skin lesions resulted to be significantly associated with systemic involvement. 
Livedo reticularis was significantly associated with ENA (p=0.007) and anti-Ro/SSA 
(p=0.036).  Palpable purpura and periungual telangiectasia were significantly associated with ANA. 
Conclusion: According to our findings, some well known associations between CLE subtypes and 
autoantibody profile were confirmed; moreover, specific association between autoantibodies and 
LE-nonspecific skin lesions were highlighted. A strict association between anti-ENA and anti-
Ro/SSA antibodies and livedo reticularis, ANA and palpable purpura, and ANA and periungual 








Cutaneous lupus erythematosus (CLE) is a chronic, relapsing autoimmune inflammatory disease 
with heterogeneous manifestations according to skin morphology, site, evolution and prognosis1,2. 
Cutaneous lesions can represent the only sign of LE and, in 23-28% of cases, can be associated with 
systemic involvement3. 
Based on Sontheimer and Gilliam's classification4, cutaneous manifestations were divided into 
"specific and diagnostic", subclassified as chronic CLE (CCLE), subacute CLE (SCLE) and acute 
CLE (ACLE). Recently, the intermittent CLE (ICLE) subtype has also been introduced5. Among 
LE-nonspecific lesions of CLE, vascular lesions, diffuse non-scarring alopecia, pigmentation 
changes, sclerodactyly and calcinosis were included4. 
Regarding serology, anti-nuclear antibodies (ANA), anti-extractable nuclear antigens (ENA) and 
anti-dsDNA antibodies are often associated with several CLE subtypes6,7. 
To date, few studies have investigated the epidemiologic characteristic of CLE. 
Inthe present study, we analysed the epidemiological, clinical and immunological data of LE in an 
Italian cross-sectional study involving patients enrolled by the Italian Group of Cutaneous 
Immunopathology (GIIP) during the period 2012-2015. We aimed to better characterise the specific 
CLE subtypes as well as LE-non specific skin lesions, evaluating the correlation between the 
clinical variants of CLE and LE-non specific skin lesions with their autoantibody pattern. We also 
considered associated diseases. 
  
  
2. MATERIALS AND METHODS 
2.1 Patients 
Consecutive patients with CLE were recruited from eight Lupus Clinics throughout Italy as part of a 
multicenter study. Demographic, clinical and laboratory data were collected at diagnosis and input 
into a clinical database. 
The diagnosis and classification of CLE was based on clinical and histological characteristics as 
well as on serological parameters9. Four subtypes of CLE were included: CCLE [localized or 
generalized discoid LE (DLE), hypertrophic lupus, LE profundus/panniculitis (LEP), and chilblain 
LE], SCLE (papulo-squamous or annular-polycyclic variants), ACLE (localized or generalized 
ACLE), and ICLE. In patients with more than one CLE subtype, the form with the highest risk of 
developing systemic involvement was declared as the main diagnosis. 
We also included SLE patients with LE specific or LE-nonspecific skin lesions, diagnosed by the 
presence of four or more American College of Rheumatology (ACR) diagnostic criteria (1982), 
revised in 19978,9. 
Serological data included ANA as well as anti-dsDNA and ENA antibodies, the latter comprising 
anti-Ro/SSA, anti-La/SSB, anti-Sm, anti- RNP and anti-histone antibodies. 
Data were compared separately between male and female patients. In the female group, a possible 
association between pregnancy or estrogens treatment with clinical features of CLE or LE-non 
specific skin lesions and autoantibody profile was also evaluated. 
Finally, for each patient, comorbidities were also reported. 
  
2.2 Statistical analysis 
At baseline, differences in demographic (age and gender) clinical features (systemic/non-systemic 
lupus) and autoantibody profile were evaluated in each subgroup using Fisher’s exact test for 
categorical variables and the nonparametric unpaired Wilcoxon test for continuous variables. For 
continuous variables, mean values with Confidence Interval 95% (CI95) were reported in the text.  
A multivariate analysis by logistic regression was performed when covariates, such as age, sex or 
systemic/non-systemic lupus, resulted to be significantly associated with both the autoantibodies 
and the investigated subtypes of CLE and LE-nonspecific skinlesions. 
Differences in demographic (age and gender) and clinical features (systemic/non-systemic LE, CLE 
subgroups) were investigatedin seven associated diseases (endocrine, respiratory, cardiovascular, 
gastrointestinal, oncological, rheumatic diseases, and Sjögren syndrome) using Fisher’s exact test. 
In all analyses, a 2-sided P value < 0.05 was considered statistically significant. Statistical analyses 




619 patients were recruited. 589 patients (95.1%) hadspecific and diagnostic manifestations of CLE 
at diagnosis, 30 patients (4.8%) presented with LE-nonspecific skin lesions only, and 130 patients 
(21.1%) featured both specific and diagnostic and LE-nonspecific lesions. A total of 160 patients 
(25.8%) had SLE. 
The total mean age at diagnosis in all CLE patients was 45.2 ± 1.2 years. The percentage of females 
was 79.6% (n=493) versus 20.4% of males (n=126). 
Results were reported in Table 1. 
  
3.2 Autoantibodies analysis 
The autoantibodies most frequently detected as positive were ANA (64.3%), followed by ENA 
(37.2%) and anti-dsDNA (17.9%) antibodies. Among ENA antibodies, we found the following 
positivity: anti-Ro/SSA (30.9%), anti-La/SSB (9.4%), anti-Sm (6.6%), anti-RNP (4.8%) and anti-
histone (1%). 
Concerning the associations between demographic, clinical characteristics and autoantibodies, ANA 
(p<0.0001), anti-dsDNA (p<0.0001), ENA (p=0.001), anti-Sm (p=0.001), anti-RNP (p=0.004), anti-
histone (p=0.005) were associated with SLE. We found a strong association between ANA 
(p<0.0001) and anti-dsDNA (p<0.0001) and gender: positive ANA and positive anti-dsDNA had a 
higher prevalence among females (78.4% vs 14.4% and 37.9% vs 4.1%, respectively). 
  
3.3 CLE subtypes analysis 
CCLE was diagnosed in 48.9% (n=303) patients, divided as follows: 35.2% (n=218) localized DLE, 
10.7% (n=66) generalized DLE, 2.4% (n=15) LEP, 0.6% (n=4) chilblain lupus and 0.3% (n=2) 
hypertrophic lupus. 
SCLE was demonstrated in 18.6% (n=115) patients: 15.7% (n=97) had an annular-polycyclic SCLE 
and 2.9% (n=18) had a papulo-squamous SCLE. 
ACLE was shown in 10.1% cases (n=63); particularly 7.9% (n=47) had a localized form of ACLE 
and 2.6% (n=16) had a generalized ACLE.  Finally, ICLE was reported in 17.4% (n=108) patients. 
Associations between autoantibodies and CLE subgroups were reported in Table2. 
A systemic involvement was found in 98.4% (n=62) ACLE patients, followed by CCLE (18.5%, 
n=56) and SCLE (12.2%, n=14) patients. None of ICLE patients had a concomitant SLE. 
  
3.3.1 CCLE 
CCLE was diagnosed in 48.9% (n=303) patients. We found ANA positivity in 60.4% (n=183) 
CCLE patients; among them, 50.5% (n=110) of the patients with localized DLE and 81.8% (n=54) 
of the patients with generalized DLE were ANA positive. All patients with LEP (n=15) 
demonstrated positive ANA versus 63.4% of patients without LEP. All patients with chilblain LE 
had positive ANA as well as systemic involvement. Only two patients had hypertrophic CLE, both 
with positive ANA.  
CCLE was negatively associated with SLE (p<0.0001), ENA (p<0.0001), anti-Ro/SSA (p<0.0001), 
anti-La/SSB (p=0.027), and anti-dsDNA (p<0.0001). Even after the multivariate logistic regression 
analysis, adjusting for covariates, this negative association was confirmed. CCLE resulted to be 
negatively associated with ENA (OR=0.51, p<0.0001), anti-Ro/SSA (OR=0.49, p<0.0001), and 
anti-dsDNA (OR=0.37, p<0.0001). Patients with CCLE had a lower prevalence of systemic 
involvement (18.5 vs 32.9%), ENA (28.4 vs 45.6%), anti-Ro/SSA (22.8 vs 38.6%), anti-La/SSB 
(6.6 vs 12.0%), and anti-dsDNA (9.6 vs 26.0%) antibodies positivity than those without a CCLE. 
Analogous evidence were observed for the localized DLE while no similar associations were 
observed for the generalized form. 
  
3.3.2 ICLE 
ICLE was reported in 17.4% (n=108) patients. Patients with ICLE were negatively associated with 
ENA (p<0.0001) and ANA (p<0.0001). Even after the multivariate logistic regression analysis, 
adjusting for covariates significantly associated with ICLE and autoantibodies, ICLE resulted to be 
negatively associated with ENA (OR=0.50, p=0.007), and ANA (OR=0.61, p=0.025). Patients 
with versus those without ICLE had a lower prevalence of ENA (22.2 vs 40.3%) and ANA (43.5 vs 
68.7%). None of the patients with ICLE fulfilled ACR criteria for SLE. 
  
3.3.3 SCLE 
SCLE was demonstrated in 18.6% (n=115) patients. SCLE was significantly associated with ENA 
(p<0.0001), anti-Ro/SSA (p<0.0001), anti-La/SSB (p<0.0001), anti-Sm (p=0.036), and anti-RNP 
(p=0.050). Even after the multivariate logistic regression analysis, adjusting for covariates 
significantly associated with SCLE and autoantibodies, SCLE resulted to be strongly associated 
with ENA (OR=5.19, p<0.0001), anti-Ro/SSA (OR=3.83, p<0.0001), anti-Sm (OR=2.95, p=0.004) 
and anti-RNP (OR=3.18, p=0.007). 
Patients with versus those without SCLE had a lower prevalence of SLE (12.2 vs 29.0%), and had a 
higher prevalence of ENA (65.2 vs 30.8), anti-Ro/SSA (53.9 vs 25.6%), anti-La/SSB (18.3 vs 
7.3%), anti-Sm (11.3 vs 5.6%), and anti-RNP (8.7 vs 4.0%). Analogous evidences emerged for the 
polycyclic-annular variant of SCLE. Concerning the papulo-squamous variant of SCLE, it was 
significantly associated with ENA (p=0.012) and anti-Ro/SSA (p=0.008). Patients with versus those 
without the papulo-squamous variant had a higher prevalence of positive ENA (66.7 vs 36.3%) and 
anti-Ro/SSA (61.6 vs 30.0%). 
  
3.3.4 ACLE 
ACLE was diagnosed in 10.1% of cases (n=63). ACLE was significantly associated with SLE 
(p<0.0001), anti-dsDNA (p<0.0001), and ANA (p<0.0001). Even after the multivariate logistic 
regression analysis, and adjusting for sex, ACLE resulted to be strongly associated withanti-dsDNA 
(OR=6.0, p<0.0001) and ANA (OR=18.1, p<0.0001). ACLE had a higher prevalence of systemic 
involvement (98.4 vs 17.8%). All patients with ACLE but one had SLE. Analogous evidences 
emerged for both the localized and generalized forms of ACLE. 
  
3.4 LE-nonspecific skin lesions analyses 
The most frequently reported LE-nonspecific skin lesions were Raynaud’s phenomenon (n=50, 
8.1%), diffuse alopecia (n=38, 6.1%), livedo reticularis (n=23, 3.7%), urticarial vasculitis (n=19, 
3.1%), palpable purpura (n=18, 2.9%), and periungual telangiectasia (n=15, 2.4%). Other LE-
nonspecific skin lesions such as thrombophlebitis, anetoderma, erythema multiforme, rheumatoid 
nodules, sclerodactyly, calcinosis cutis and mucinosis occurred in less than 2% of the 619 patients. 
Associations between autoantibodies and CLE subgroups were reported in Table 3. 
A systemic involvement was found in 64% of patients with LE-nonspecific skin lesions. 
Particularly, SLE was found in 80% (n=12) patients with periungual telangiectasia, followed by 
patients with urticarial vasculitis (79%, n=15), Raynaud’s phenomenon (68%, n= 34), livedo 
reticularis (56.5%, n=13), diffuse alopecia (50%, n=19) and palpable purpura (50%, n=9). 
  
3.4.1 Raynaud’s phenomenon 
Raynaud’s phenomenon was found in 8.1% of patients (n=50). Raynaud’s phenomenon was 
significantly associated with SLE (p<0.0001). Patients with versus those without Raynaud’s 
phenomenon had a higher prevalence of systemic involvement (68.0 vs 22.1%). 
  
3.4.2 Diffuse non-scarring alopecia 
Diffuse non-scarring alopecia was found in 6.1% of patients (n=38). Diffuse non-scarring alopecia 
was significantly associatedwith SLE (p=0.001): patients with versus those without diffuse alopecia 
had a higher prevalence of systemic involvement (50.0 vs 24.3%). 
  
3.4.3 Livedo reticularis 
Livedo reticularis was found in 3.7% (n=23) of patients. Livedo reticularis was significantly 
associated with SLE (p=0.007), ENA (p=0.007), and anti-Ro/SSA (p=0.036). Even after the 
multivariate logistic regression, adjusting for systemic/non-systemic form, livedo reticularis 
resulted to be associated with ENA (OR=2.80, p=0.023) and anti-Ro/SSA, even if at the limit of 
significance (OR=2.31, p=0.053). Patients with versus those without livedo reticularis had a higher 
prevalence of systemic involvement (56.5 vs 24.7%), positive ENA (65.2 vs 36.1%) and positive 
anti-Ro/SSA (52.2 vs 30.0%). 
  
3.4.4 Urticarial vasculitis 
Urticarial vasculitis was found in 3.1% of patients (n=19).  Urticarial vasculitis was associated with 
SLE (p<0.0001): patients with versus those without urticarial vasculitis had a higher prevalence of 
systemic involvement (79.0 vs 24.2%). 
  
3.4.5 Palpable purpura 
Palpable purpura was found in 2.9% of patients (n=18). Palpable purpura was significantly 
associated with SLE (p=0.026) and ANA (p=0.001): patients with versus those without palpable 
purpura had a higher prevalence of systemic involvement (50.0 vs 25.1%). All patients with 
palpable purpura had a positive ANA. 
  
3.4.6 Periungual telangiectasia 
Periungual telangiectasia was found in 2.4% of patients (n=15). Periungual telangiectasia was 
significantly associated with SLE (p<0.0001), and ANA (p=0.002): patients with versus those 
without periungual telangiectasia ad a higher prevalence of systemic involvement (80.0 vs 24.5%). 
All patients with periungual telangiectasia had a positive ANA. 
  
3.5 drug-induced CLE 
Drug-induced (DI) LE was found in 3.2% patients, ofwhom, 60% had CCLE, 30% SCLE and 10% 
LE-nonspecific skin lesions. DI-LE was significantly associated with anti-histone antibodies 
(p=0.014), while a negative association between DI-LE and anti-Ro/SSA antibodies (p=0.047) was 
demonstrated. 
  
3.6 ACR criteria 
Photosensitivity was found in 47.8% of patients. It was associated with ENA (p=0.027), anti-
Ro/SSA (p=0.001), and anti-dsDNA (p=0.014) antibodies. 
Arthritis was found in 18.9% of patients. It was associated with anti-dsDNA (OR= 4.2; 
p=<0.0001), ENA (p=0.003) anti-Ro/SSA (p=0.005). 
Oral ulcers were present in 8.2% (n=51) of patients: 33.3% had CCLE, 22% ACLE, 15.6% SCLE 
and 29.1% had LE-nonspecific skin lesions);84.3% had a systemic involvement. Oral ulcers were 
associated with female sex (p=0.018), and anti-dsDNA (OR= 4.2; p<0.0001). 
Renal disorder was found in 3.5% of patients. It was associated with SLE and anti-dsDNA 
(p<0.0001). 
Serositis was found in 3.4% of patients. They were associated with SLE and anti-RNP (p= 0.015). 
Neurologic disorder was found in 2.1% of patients. It was associated with SLE anti-dsDNA 
(p<0.0001). 
  
3.7 Smoking, pregnancy and estrogens treatments 
180 patients (29.6%) were smokers. A strong association between smoking and ICLE was 
demonstrated (p=0.002). ICLE had the highest percentage of smokers (n=46, 42.6%) in comparison 
with the other subtypes (CCLE 29.7%, ACLE 27.4%, SCLE 20.9%). On the contrary, a negative 
association between SCLE and smoking was found (p=0.024). SCLE had the lowest percentage of 
smokers in comparison with the other subtypes (31.6% vs 20.9%). 
A strong association between smoking and CCLE patients with systemic involvement was also 
shown (p=0.013). Patients with CCLE and systemic involvement were smokers more often than 
patients with CCLE without SLE (44.6% vs 29.7%). LE-nonspecific skin lesion, followed 
by cutaneous small vessel leukocytoclastic vasculitis and non-scarring alopecia. All these lesions 
appeared in the active phases of the disease. Similar data were found in a recent study on 260 
patients with SLE32. On thecontrary, Biazar et al. showed a higher incidence of diffuse alopecia 
followed by Raynaud's phenomenon. ACLE was the subtype which showed LE-nonspecific lesions 
more often than SCLE, but the incidence of LE-nonspecific skin lesions in ACLE was not 
significantly different from CCLE11. 
Smoking is considered a risk factor for CLE33, especially for ICLE patients. In comparison with the 
literature data, our study showed a lower percentage of CLE smokers (29.6% vs 47.2%). We 
confirmed the negative influence of smoking on ICLE patients, but we added some relevant details, 
such as the association between smoking and CCLE patients with systemic involvement and 
between smoking and SLE patients with LE-nonspecific skin lesions. Thus, smoking represents a 
risk factor for CLE and SLE patients and smoking cessation programs should be encouraged, 
especially in these subgroups of patients.  
Previous epidemiologic studies have shown that patients with LE have an increased risk of 
comorbidity34-41. In our study, we found an increased risk of Sjögren syndrome, as well as 
endocrine and respiratory diseases in SLE patients, regardless the CLE subtypes. An association 
among cardiovascular and gastrointestinal diseases and age was shown; accordingly, patients with 
versus those without such diseases were older.  
Concerning oncological diseases, it has recently been shown that patients with SCLE42 and, in few 
cases, with DLE43 have a significantly increased cancer risk, especially for oral cancer, lymphomas, 
respiratory cancer and non-melanoma skin cancer44. In our study we did not find any correlation 
among CLE and cancers. The only significant association was with age: elderly had a higher risk of 
cancers as it is shown in general population45. 
Finally, no significant associations were demonstrated among rheumatic diseases and demographic 
and clinical characteristics of CLE patients. However, since our study was not prospective, we 




The present study provides important information on epidemiologic data in a cohort of 619 CLE 
patients. We confirmed some known associations between autoantibodies and CLE subtypes, 
adding some relevant details for diagnostic purposes, such as the association between anti-
dsDNAantibodies and oral ulcers, regardless a systemic involvement. Since oral ulcers are often 
associated with SLE, we suggest to strictly monitor these patients in order to evaluate a possible 
systemic evolution. The same conclusions can be drawn about LE-nonspecific skin lesions, that 
were significantly associated with SLE. 
Moreover, since smoking has a higher prevalence among CLE patients, we suggest to discuss with 
CLE patients its role in inducing or worsening skin and systemic lesions, in order to interrupt 
smoking at soon at possible. 
Interestingly, our results showed that patients with SCLE had a lower prevalence of SLE compared 
to CCLE and ACLE subtypes. None of ICLE patients showed a systemic involvement. 
Finally, patients with CLE have a higher incidence of associated diseases, such as thyroid diseases, 
especially in cases of systemic involvement. Thus, we suggest to evaluate all the patients with CLE 
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